Heron Therapeutics (HRTX) PT Lowered to $14 at Needham & Company on Slower Zynrelef Launch and Financing Overhang
Tweet Send to a Friend
Needham & Company analyst Serge Belanger lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $14.00 (from $16.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
